Investigating how blood type and genetic factors contribute to heparin-induced thrombocytopenia
ABO and Immunogenetic Variation in the Pathogenesis of Heparin-Induced Thrombocytopenia
This study is looking at how some people might have a bad reaction to heparin, a common blood thinner, and aims to find out if certain genes or immune responses can help predict who might be at risk, so doctors can better protect patients before they start treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10886615 on NIH RePORTER |
What this research studies
This research focuses on understanding heparin-induced thrombocytopenia (HIT), a serious immune reaction that can occur in patients receiving heparin, a common blood thinner. The study aims to identify genetic variations and immune responses that may predict who is at risk for developing HIT. By analyzing blood samples and genetic data, researchers hope to differentiate between harmful and harmless antibodies related to HIT. This could lead to the development of biomarkers that help clinicians identify patients at risk before they receive heparin treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are scheduled to receive heparin treatment and have specific ABO blood types or genetic markers.
Not a fit: Patients who do not require heparin treatment or have no history of adverse reactions to heparin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer heparin use by identifying patients at risk for HIT, potentially saving lives and reducing complications.
How similar studies have performed: Previous research has shown promise in identifying genetic factors related to HIT, but this study aims to explore novel approaches that have not been extensively tested.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Karnes, Jason Hansen — University of Arizona
- Study coordinator: Karnes, Jason Hansen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.